Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Adding durvalumab and olaparib to chemo extends survival in endometrial cancer. Interim data from the phase 3 DUO-E trial, presented at ESMO 2026, showed that carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with olaparib improved median overall survival to 51.1 months vs. 39.6 months with chemo alone — though the result didn't cross the statistical significance threshold. The benefit was especially notable in patients with mismatch repair-deficient tumors.
Adding immunotherapy and a PARP inhibitor to standard chemo boosts survival in advanced endometrial cancer — but just misses the statistical bar.
Interim overall survival (OS) data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress in Madrid, showed that first-line carboplatin/paclitaxel (CP) plus durvalumab, followed by maintenance durvalumab with or without olaparib, outperformed CP alone in patients with advanced or recurrent endometrial cancer. At a median follow-up of ~52 months, the durvalumab + olaparib arm achieved a median OS of 51.1 months vs. 39.6 months in the control arm — an 11.5-month improvement — though neither experimental arm crossed its prespecified significance threshold.
The most notable results came in the mismatch repair-deficient (dMMR) subgroup, where median OS was not reached in either experimental arm vs. 50.2 months in the control arm, with a 57% reduction in the hazard of death for the durvalumab + olaparib arm. No new safety signals were identified.
By the Numbers:
Why it matters: These results reinforce durvalumab ± olaparib as a meaningful first-line option for advanced endometrial cancer, particularly for dMMR patients. Final OS analysis will determine whether the survival benefit reaches formal statistical significance.
